On April 29, 2025 NEUVOGEN, Inc. ("NEUVOGEN THERAPEUTICS" or "NEUVOGEN"), a San Diego based biotechnology company, reported that it will present data that its next generation whole tumor cell vaccine (NGEN-143) activates T cells that recognize a diverse antigen repertoire (Press release, NEUVOGEN, APR 29, 2025, View Source [SID1234652332]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These findings support that NGEN-143 can deliver an unprecedented breadth of targets and activate cytotoxic T cells, as compared to other currently available cancer vaccines, making NGEN-143 a better potential option for patients" said Todd Binder, Chief Executive Officer of NEUVOGEN. "Our dedicated team is eager to bring this new cancer vaccine forward to treat patients with non-small cell lung cancer (NSCLC)."
Key Findings:
In a fully human in vitro system, NGEN-143 expands effector T cells against a broad repertoire of both tumor-associated antigens and common shared neo-antigens across a wide range of HLA types.
NGEN-143 activates polyfunctional, cytotoxic T cells; the response is dominated by CD8+ cells without any evidence of antigenic competition. CD4+ T cell responses are skewed toward CD4+ Th1 cells over CD4+ Th2 cells.
NGEN-143 activated T cells efficiently kill human tumor cells in a caspase-3 dependent manner.
In the ‘immune warm’ CT26 mouse tumor model, vaccine abrogates or slows tumor growth – durable protection against rechallenge supports efficient induction of immune memory; vaccine + αPD1 improved survival over αPD1 monotherapy.
In the ‘immune cold’ B16F10 mouse tumor model, our vaccine approach inhibits tumor growth and prolongs survival; vaccine + αPD1 improved survival.
Bernadette Ferraro, Ph.D., NEUVOGEN’s Vice President, Immuno-oncology, is scheduled to present "An optimized off-the-shelf whole tumor cell vaccine activates T cells that recognize a diverse antigen repertoire with potential to provide meaningful clinical benefit to patients with NSCLC," at AACR (Free AACR Whitepaper) on Tuesday, April 29 from 2:00 – 5:00 PM CT. A copy of the poster will be made available for download at neuvogen.com/our-science after the meeting concludes.